Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and
preventing hospitalization in patients with heart failure and reduced ejection fraction …
preventing hospitalization in patients with heart failure and reduced ejection fraction …
[HTML][HTML] Real-world eligibility for sacubitril/valsartan in heart failure with reduced ejection fraction patients in Korea: data from the Korean Acute Heart Failure (KorAHF) …
Methods From March 2011 to February 2014, a total of 5,625 patients who were admitted for
HF were enrolled in Korea. After excluding HF patients with left ventricular ejection fraction> …
HF were enrolled in Korea. After excluding HF patients with left ventricular ejection fraction> …
Clinical Representativeness of the PARADIGM-HF Study in an Outpatient Cohort of Patients with Heart Failure, Including Chagas Disease, Treated According to …
RMFL Silva, PVC Garcia… - … and Angiology: An …, 2020 - eprints.go2submission.com
Background: In the PARADIGM-HF trial there was a 20% reduction in hospitalization and
cardiovascular mortality in patients with heart failure (HF) and treated according to guideline …
cardiovascular mortality in patients with heart failure (HF) and treated according to guideline …
Angiotensin receptor neprilysin inhibitors—2019 update
G Chalikias, D Tziakas - Cardiovascular Drugs and Therapy, 2020 - Springer
An abundance of new data regarding the use of the novel drug compound
sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the …
sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the …
Effect of sacubitril–valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels
Y Duan, M Yu, Y Xu - Tropical Journal of Pharmaceutical Research, 2023 - ajol.info
Methods: A total of sixty CHF patients were divided randomly into two groups of thirty
patients each (conventional and sacubitril-valsartan groups, respectively). Conventional anti …
patients each (conventional and sacubitril-valsartan groups, respectively). Conventional anti …
[PDF][PDF] Clinical Evidence of Initiating a Very Low Dose of Sacubitril/Valsartan; Beyond the PARADIGM-HF and PIONEER-HF: A Prospective Observational Analysis
Aims Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death
and preventing hospitalization in patients with heart failure and reduced ejection fraction …
and preventing hospitalization in patients with heart failure and reduced ejection fraction …
INDICAȚIILE ACTUALE ALE COMBINAȚIEI TERAPEUTICE SACUBITRIL/VALSARTAN ÎN INSUFICIENȚA CARDIACĂ.
N Cojocaru, D Clapon, L Jinga… - Brasov Medical …, 2020 - search.ebscohost.com
În ultimele decenii, prevalența insuficienței cardiace a crescut la nivel mondial. În zilele
noastre, speranța de viață și calitatea vieții a acestor pacienți au crescut datorită …
noastre, speranța de viață și calitatea vieții a acestor pacienți au crescut datorită …
Indicațiile actuale ale combinației terapeutice sacubitril/valsartan în insuficiența cardiacă|[Current indications for sacubitril/valsartan therapeutic combination in …
N Cojocaru, D Clapon, L Jinga… - Jurnal Medical …, 2020 - webbut.unitbv.ro
The prevalence of heart failure has increased globally in recent decades. Nowadays, life
expectation and quality of life of these patients has increased thanks to innovative therapies …
expectation and quality of life of these patients has increased thanks to innovative therapies …
Sacubitril/Valsartan: suivi d'une cohorte de patients insuffisants cardiaques en vie réelle
J Lemonnier, A Rajkumar, M Gautier… - … Hospitalier et Clinicien, 2020 - Elsevier
Résumé Introduction Le Sacubitril/Valsartan a été développé dans le traitement de
l'insuffisance cardiaque (IC) à fraction d'éjection abaissée. Dans l'étude PARADIGM-HF, il a …
l'insuffisance cardiaque (IC) à fraction d'éjection abaissée. Dans l'étude PARADIGM-HF, il a …